QC
UNCY icon

Quadrature Capital’s Unicycive Therapeutics UNCY Stock Holding History

Quadrature Capital’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$184K Sell
27,917
-11,197
-29% -$73.4K ﹤0.01% 1139
2025
Q4 		$226K Buy
+39,114
New +$209K ﹤0.01% 940

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrature Capital's UNCY Position: Q1 2026 in Review

Quadrature Capital reduced its Unicycive Therapeutics (UNCY) stake by 29% in Q1 2026, selling an estimated $73.4K and leaving 27,917 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #1139.

Quadrature Capital first reported a position in UNCY in Q4 2025 and has held it in 2 quarters since. The position peaked at $226K in Q4 2025. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Quadrature Capital held 27,917 shares of Unicycive Therapeutics worth $184K as of Q1 2026.
  • Quadrature Capital sold 11,197 Unicycive Therapeutics shares in Q1 2026, an estimated $73.4K.
  • Unicycive Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1139 holding.
  • Quadrature Capital first reported a position in Unicycive Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Quadrature Capital's Unicycive Therapeutics position peaked at $226K in Q4 2025.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.